3 research outputs found
Baseline factors associated with anemia during pegylated interferon plus ribavirin combination therapy for chronic hepatitis C
Universidade Federal de SĂŁo Paulo, Hepatitis Div, Dept Gastroenterol, SĂŁo Paulo, BrazilUniversidade Federal de SĂŁo Paulo, Hepatitis Div, Dept Gastroenterol, SĂŁo Paulo, BrazilWeb of Scienc
InfluĂȘncia do gĂȘnero no tratamento da hepatite C crĂŽnica genĂłtipo 1
INTRODUCTION: Although various studies have been published regarding the treatment of chronic hepatitis C (CHC) with peginterferon (Peg-IFN) and ribavirin, little is known regarding the real impact of gender on the characteristics that influence the effectiveness and safety of antiviral treatment for CHC patients. The objective of this study was to evaluate the influence of gender on HCV treatment outcomes. METHODS: A retrospective analytical study was conducted among selected carriers of CHC genotype 1, who were treated with Peg-IFN α-2b at a dose of 1.5 ÎŒg/kg or Peg-IFN α-2a at a dose of 180 ÎŒg/week plus a ribavirin dose of 1,000-1,250 mg/day, according to weight, between 2001 and 2007. RESULTS: Among 181 patients undergoing treatment, the mean age was 46.4 ± 11.0 years and 46% were women. At baseline, 32% of the patients had advanced fibrosis (F3-F4 Scheuer), and 83% of the subjects had viral load > 400,000 IU/ml, without significant difference between the genders (p = 0.428 and p = 0.452, respectively). When compared with men, women had higher incidence of many adverse events such as anemia (p < 0.001) and higher need for dose reduction, for both Peg-IFN (p = 0.004) and ribavirin (p = 0.006). However, the rate of sustained virological response (SVR) did not differ between the genders: 45% (female) vs 41% (male); p=0.464. CONCLUSIONS: This study suggests that women and men react differently to combined therapy, especially in relation to the incidence of adverse events and the need for dose modification. Nevertheless, these differences do not influence the SVR rate.INTRODUĂĂO: Apesar dos vĂĄrios estudos publicados a respeito do tratamento da hepatite C crĂŽnica (CHC) com Peg-Interferon (Peg-IFN) e ribavirina, se desconhece o real impacto do gĂȘnero sobre as caracterĂsticas que influenciam a eficĂĄcia e a segurança da terapia antiviral em portadores de CHC. O objetivo deste estudo foi avaliar a influĂȘncia do gĂȘnero no tratamento da CHC. MĂTODOS: Foi realizado um estudo analĂtico retrospectivo de portadores de CHC genĂłtipo 1 tratados com Peg-IFN α-2b na dose de 1,5ÎŒg/kg ou Peg-IFN α-2a na dose de180ÎŒg/sem associado Ă ribavirina 1.000-1.250 mg/dia, de acordo com o peso, entre 2001 e 2007. RESULTADOS: Entre 181 pacientes submetidos ao tratamento, a mĂ©dia de idade foi de 46,4±11,0 anos e 46% eram mulheres. No prĂ©-tratamento, 32% dos pacientes apresentavam fibrose avançada (F3-F4 Scheuer), e 83% dos indivĂduos apresentavam carga viral >400.000IU/mL, sem diferença significativa entre os gĂȘneros (p=0,428 e p=0,452, respectivamente). Quando comparadas aos homens, as mulheres exibiram maior incidĂȘncia de eventos adversos como anemia (p<0,001) e maior necessidade de redução de dose tanto do Peg-IFN (p=0,004) quanto da ribavirina (p=0,006). Entretanto, as taxas de resposta virolĂłgica sustentada (RVS) nĂŁo diferiram entre os gĂȘneros (45% (mulheres) . vs 41% (homens); p=0,464). CONCLUSĂES: Este estudo sugere que homens e mulheres reagem Ă terapia combinada de forma diferente, especialmente com relação aos eventos adversos e Ă necessidade de modificação de dose. No entanto, essas diferenças nĂŁo influenciam as taxas de RVS